Glaxosmithkline Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4yjf9cgw5hc2dgajyh0qd5wc.pdf

Key Takeaways


Supply Constraints & Recovery

Akshikar: "I can only reassure you, given the visibility and the oversight that I along with the management team have, beginning the month of April and Q1 of our new financial year, we don't have any supply constraints."

Portfolio Performance

Akshikar: "in spite of having 8 to 10 generic versions of the combination, of the triple combination, I don't think we have the -- still anyone which has a device or the quality of ease of usage as Trelegy Ellipta."

Innovation Pipeline & Launches

Akshikar: "for the first time you have, I think, 25% of the patients getting complete functional cure. And that's from a baseline of almost nothing existing, you have something which is for the first time actually talking of a potential functional cure."

Margins & Reinvestment

Akshikar: "Our objective will be to maintain the margins and not to -- we would love to reinvest in the business... we would rather invest that money in growing the business with the expectation that we are able to hold the margins."

Strategic Bets: Adult Vaccines & Oncology Access

Akshikar: "the next 12 months, this coming financial year, especially for shingles prevention vaccine or Shingrix, will be path-breaking."

Guidance & Commitments

CommitmentSpecificsTimeline
Supply constraints resolvedNo supply constraints; alternative contingencies in placeFrom April / Q1 FY27
GenMed growth recoveryReturn to 6–8% top-line growthFY27 (post-supply normalisation)
Double-digit growth ambitionStated intent undiluted, innovation-ledOngoing (no terminal date)
At least one significant launchFor an unmet need with significant value per assetNext four quarters
Two oncology launches, one adult vaccine launchSpecific count of near-term launchesNext six months
Bepirovirsen market authorizationEstimated approval in IndiaNext six months / this financial year
Oncology public-account accessProgress on CGHS, Army, Railways, ESIC accountsNext six to eight months
Freshness index targetInnovative portfolio at ~10% of top-lineNo date (directionally stated)
Margins maintained, not expandedHold margins and reinvest for launchesOngoing
Liver disease news flowBepirovirsen and Efruxifermin updatesNext 12–18 months

Key Metrics

MetricQ4 FY26
Revenue₹64,000–₹65,000 cr (industry per IQVIA), GSK standalone sales up 2% YoY
EBITDA margin35%, improved 1 ppt YoY on better gross margins and cost management
EBITDA growth5% YoY
PAT growth6% YoY
Full-year revenue growth2% YoY
Full-year EBITDA margin34%, improved 290 bps YoY
Full-year PAT (excl. exceptionals)>₹1,000 cr, first time crossing this milestone
Full-year EPS₹59.6 per share, up 10% YoY
Gross margin (full year)Up 190 bps YoY
Return on capital employed (full year)61.0%
Cash position (year-end)₹2,745 cr
Final dividend₹57 per share
Innovative portfolio contribution6% of Q4 sales, up from ~2% on a like-to-like basis in prior-year Q4
Pediatric vaccines growth (full year)9%
Vaccines portfolio blended growth (full year)>11–12%
General Medicines growth (full year)~flat, underlying growth 3–4% adjusted for >₹100 cr supply-constraint impact
Supply-constraint impact on Q4 top-lineShaved off ~3–3.5% of growth
NLEM exposure~40% of business
Oncology field force~25 people for solid tumors, hematology team recruitment started
Ongoing clinical trials in India26 trials, up from 16 two quarters ago
Multiple myeloma annual incidence (India)~18,000 new cases, prevalence ~40,000–45,000 patients